World News: 13:32 GMT Friday 7th December 2018. [Myriad Genetics, Inc. via Globe Newswire via SPi World News]
SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict at the San Antonio Breast Cancer Symposium in San Antonio, Texas. One of the key findings is that EndoPredict high-risk patients had a better outcome with adjuvant chemotherapy compared to endocrine therapy alone.“There is a critical need for improved test options that optimally combine genetic information from the tumor with important clinical features and help clinicians develop precision treatment plans for women with breast cancer,” said Johannes Ettl, M.D., lead investigator and head of the Gyneco-Oncological Outpatient Clinic, TUM “We are excited to present the first-ever prospective outcome data for the EndoPredict test which demonstrated the ability to predict disease free survival and guide decision of adjuvant chemotherapy use in hormone receptor positive, HER2-negative breast cancer.”The key data being presented at SABCS are summarized below.
This prospective study evaluated outcomes data of patients whose adjuvant systemic chemotherapy recommendation was based on the EndoPredict (EPclin) test result. All patients were evaluated for treatment compliance, local recurrence, distant metastases and survival. A total of 373 patients with HR+, HER2- early breast cancer pts with 0-3 positive lymph nodes were enrolled between March 2012 and March 2015. The EndoPredict test allocated 238 pts (63.8 percent) in the low-risk group and 135 pts (36.2 percent) in the high-risk group. Of these, 128 patients were recommended to undergo adjuvant chemotherapy in addition to endocrine therapy and 92 (72 percent) of patients were compliant having received standard-of-care chemotherapy.
“In this first analysis of clinical data from our breast center, patients who were classified as high risk by EndoPredict and who received chemotherapy experienced a 68 percent reduction in relapse compared to patients who did not receive the recommended chemotherapy,” said Prof. Marion Kiechle, M.D., director of the Women´s Hospital, TUM. “After a median follow up of 3.5 years, the results approached statistical significance (p=0.06). For the first time, we looked at prospective data which demonstrated that EndoPredict has the capacity to predict chemotherapy benefit in EPclin high-risk patients. Future analyses with longer follow up will shed further light on this chemopredictive ability of the EndoPredict test.”
Media Contact: Ron Rogers (801) 584-3065
Investor Contact: Scott Gleason(801) 584-1143
Globe Newswire: 13:32 GMT Friday 7th December 2018
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.